Core Insights - Veradermics has completed enrollment in its second Phase 3 clinical trial for VDPHL01, a treatment for male pattern hair loss, marking a significant milestone in the development of this innovative therapy [1][3] Company Overview - Veradermics is a late clinical-stage biopharmaceutical company founded by dermatologists, focusing on developing therapeutics for aesthetic and dermatological conditions [5] - The company aims to create a portfolio of products targeting high-prevalence dermatologic conditions, with VDPHL01 being its lead program for treating pattern hair loss [5][6] Product Details - VDPHL01 is an oral, extended-release formulation of minoxidil designed to enhance hair restoration while minimizing cardiac side effects [2][6] - The proprietary formulation uses a gel matrix for a steady release of minoxidil, aiming for consistent hair growth without exceeding cardiac activity thresholds [2][6] Clinical Trials - The completed Phase 3 male trial, named '304', involved 536 participants and evaluated the safety and efficacy of VDPHL01 over 52 weeks [3] - The co-primary endpoints of the trial include changes in non-vellus hair count and patient-reported hair coverage benefits at 24 weeks [3] - Veradermics anticipates topline data from its first Phase 2/3 trial in males in the first half of 2026 [4] Market Context - Pattern hair loss affects approximately 80 million people in the U.S., with a significant impact on quality of life, including mental health issues [8] - There have been no new FDA-approved treatments for pattern hair loss in nearly 30 years, highlighting a substantial market opportunity for innovative therapies like VDPHL01 [8] - The market for pattern hair loss treatments is projected to reach around $30 billion by 2028, driven by high demand for effective solutions [8]

Core Insights - VeraDermics, TG-17, and Colombier Acquisition III went public on February 4, 2026, with significant stock price increases on their debut. Group 1: VeraDermics (MANE) - VeraDermics opened at $34 per share, a 100% increase from the offering price, and closed at $37.75, marking a 122.06% rise with a total market capitalization of $1.259 billion [1][2] - The company issued 15.08 million shares at $17 each, raising $256 million, which will be used for physician education, brand promotion, marketing, infrastructure, and other general corporate purposes [2] - VeraDermics is a late-stage biopharmaceutical company focused on developing innovative therapies for aesthetic and dermatological issues, currently working on an oral, non-hormonal therapy named VDPHL01 for treating PHL [2] Group 2: TG-17 (OBAI) - TG-17 opened at $20 per share, a 60.94% increase, and closed at $33, resulting in a 167.21% rise with a total market capitalization of $457 million [3][6] - The company went public through a direct listing without issuing new shares or raising capital [6] - TG-17 provides AI-driven personal safety services and operates in 28 countries, offering 14 types of monitoring and emergency coordination services [6] Group 3: Colombier Acquisition III (CLBRU) - Colombier Acquisition III issued 26 million units at $10 each, raising $260 million [7] - The company is a special purpose acquisition company (SPAC) initiated by Omeed Malik, focusing on sectors such as technology, advanced manufacturing, defense, energy, and digital infrastructure [7]

Core Viewpoint - Veradermics has announced the pricing of its upsized initial public offering (IPO) of 15,077,647 shares at $17.00 per share, aiming to raise approximately $256.3 million before expenses [1] Company Overview - Veradermics is a late clinical-stage biopharmaceutical company founded by dermatologists, focusing on innovative therapeutics for aesthetic and dermatological conditions [1] - The company is developing a focused portfolio of aesthetic dermatology product candidates, with a lead program, VDPHL01, targeting pattern hair loss [1] Initial Public Offering Details - The IPO is set to close on February 5, 2026, subject to customary closing conditions, with trading on the New York Stock Exchange expected to begin on February 4, 2026, under the ticker symbol "MANE" [1] - The underwriters have a 30-day option to purchase an additional 2,261,647 shares at the IPO price [1] Product Development - VDPHL01 is being developed as an oral, non-hormonal treatment for pattern hair loss, designed to enhance the effectiveness of minoxidil while minimizing cardiac risks [1] - The company has completed enrollment in its Phase 2/3 clinical trial for VDPHL01 for male pattern hair loss and is actively enrolling women for the first oral treatment trial for female pattern hair loss [2]

Group 1: Recent IPOs - Last week, 15 new stocks were listed, including one direct listing company, Public Policy Holding (PPHC), which raised $50.84 million by issuing 4.15 million shares at $12.25 per share [1] - York Space System (YSS) raised $629 million by issuing 18.5 million shares at $34 per share [1] - Picpay (PICS) raised $434 million by issuing 22.86 million shares at $19 per share [1] - Ethos Technologies (LIFE) raised $200 million by issuing 10.53 million shares at $19 per share [1] Group 2: Upcoming IPOs - Jaguar Uranium Corp. plans to list on NYSE MKT with the ticker JAGU on February 3, 2026, aiming to raise up to $30 million by issuing 6 million shares at $4 to $6 per share [3][5] - VeraDermics, Inc. plans to list on NYSE with the ticker MANE on February 4, 2026, aiming to raise up to $214 million by issuing 13.35 million shares at $14 to $16 per share [8] - Eikon Therapeutics, Inc. plans to list on NASDAQ with the ticker EIKN on February 5, 2026, aiming to raise up to $318 million by issuing 17.65 million shares at $16 to $18 per share [10] - Bob's Discount Furniture, Inc. plans to list on February 5, 2026, aiming to raise up to $370 million by issuing 19.45 million shares at $17 to $19 per share, with projected revenue of $1.719 billion and a net profit of $80.7 million for the first nine months of 2025 [14] - Forgent Power Solutions, Inc. plans to list on NYSE with the ticker FPS on February 5, 2026, aiming to raise up to $1.624 billion by issuing 56 million shares at $25 to $29 per share, with revenue of $283 million and a net profit of $15.56 million for the last three months ending September 30, 2025 [18] - Once Upon a Farm, PBC plans to list on February 6, 2026, aiming to raise up to $209 million by issuing 11 million shares at $17 to $19 per share, with revenue of $177 million and a net loss of $39.76 million for the first nine months of 2025 [22] - Liftoff Mobile, Inc. plans to list on NASDAQ with the ticker LFTO on February 6, 2026, aiming to raise up to $762 million by issuing 25.4 million shares at $26 to $30 per share, with revenue of $492 million and a net loss of $25.65 million for the first nine months of 2025 [25] - Agomab Therapeutics NV plans to raise up to $213 million by issuing 12.5 million shares at $15 to $17 per share, with no revenue and a loss of $45.15 million for the first nine months of 2025 [28]

As filed with the Securities and Exchange Commission on January 28, 2026. Registration No. 333-292657 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Veradermics, Incorporated (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 84-3304423 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...

As filed with the Securities and Exchange Commission on January 9, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Veradermics, Incorporated (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 84-3304423 (I.R.S. Employer Identification No.) 470 James St. New ...